Taurine ameliorates neuropathy via regulating NF-κB and Nrf2/HO-1 signaling cascades in diabetic rats

Food and Chemical Toxicology

Volumn 71, Issue , 2014, Pages 116-121

  Agca, Can Ali ^a   Tuzcu, Mehmet ^b   Hayirli, Armagan ^b   Sahin, Kazim ^c  

^a BINGOL UNIVERSITY   (Turkey)

^b FIRAT UNIVERSITY   (Turkey)

^c ATATÜRK UNIVERSITY   (Turkey)

Author keywords

Diabetic neuropathy; HO 1; NF B; Nrf2; Oxidative stress; Taurine

Indexed keywords

GLUCOSE; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MALONALDEHYDE; TAURINE; TRANSCRIPTION FACTOR NRF2; WATER; NFE2L2 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; BODY WEIGHT; BRAIN TISSUE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HYPERGLYCEMIA; MALE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; RAT; REVIEW; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; WEIGHT REDUCTION; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ENZYME REPRESSION; METABOLIC REGULATION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TREATMENT DURATION; VITAMIN SUPPLEMENTATION; ANIMAL; DIABETIC NEUROPATHIES; EXPERIMENTAL DIABETES MELLITUS; METABOLISM;

RATTUS;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; HEME OXYGENASE-1; NF-E2-RELATED FACTOR 2; NF-KAPPA B; OXIDATIVE STRESS; RATS; SIGNAL TRANSDUCTION; TAURINE;

EID: 84903703490     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2014.05.023     Document Type: Review

References (64)

1. Anitha M., Abraham P.M., Paulose C.S. Striatal dopamine receptors modulate the expression of insulin receptor, IGF-1 and GLUT-3 in diabetic rats: effect of pyridoxine treatment. Eur. J. Pharmacol. 2012, 696:54-61.
2. Baker R.G., Hayden M.S., Ghosh S. NF-kappaB, inflammation, and metabolic disease. Cell Metab. 2011, 13:11-22.
3. Banerjee R., Vitvitsky V., Garg S.K. The undertow of sulfur metabolism on glutamatergic neurotransmission. Trends Biochem. Sci. 2008, 33:413-419.
4. Barim O., Karatepe M. The effects of pollution on the vitamins A, E, C, betacarotene contents and oxidative stress of the freshwater crayfish, Astacus leptodactylus. Ecotoxicol. Environ. Saf. 2010, 73:138-142.
5. Cameron N.E., Cotter M.A. Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway. Curr. Drug Deliv. 2008, 9:60-67.
6. Chang K.J., Kwon W. Immunohistochemical localization of insulin in pancreatic beta-cells of taurine-supplemented or taurine-depleted diabetic rats. Adv. Exp. Med. Biol. 2000, 483:579-587.
7. Das J., Vasan V., Sil P.C. Taurine exerts hypoglycemic effect in alloxan-induced diabetic rats, improves insulin-mediated glucose transport signaling pathway in heart and ameliorates cardiac oxidative stress and apoptosis. Toxicol. Appl. Pharmacol. 2012, 258:296-308.
8. Dawson R., Liu S., Eppler B., Patterson T. Effects of dietary taurine supplementation or deprivation in aged male Fischer 344 rats. Mech. Ageing Dev. 1999, 107:73-91.
9. Duelli R., Kuschinsky W. Brain glucose transporters: relationship to local energy demand. News Physiol. Sci. 2001, 16:71-76.
10. Duelli R., Schrock H., Kuschinsky W., Hoyer S. Intracerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucoseutilization in rats. Int. J. Dev. Neurosci. 1994, 12:737-743.
11. Duelli R., Maurer M.H., Staudt R., Heiland S., Duembgen L., Kuschinsky W. Increased cerebral glucose utilization and decreased glucose transporter Glutl during chronic hyperglycemia in rat brain. Brain Res. 2000, 858:338-347.
12. Edwards J.L., Vincent A.M., Cheng H.T., Feldman E.L. Diabetic neuropathy: mechanisms to management. Pharmacol. Ther. 2008, 120:1-34.
13. Franconi F., Di Leo M.A., Bennardini F., Ghirlanda G. Is taurine beneficial in reducing risk factors for diabetes mellitus?. Neurochem. Res. 2004, 29:143-150.
14. Franconi F., Loizzo A., Ghirlanda G., Seghieri G. Taurine supplementation and diabetes mellitus. Curr. Opin. Clin. Nutr. Metab. Care 2006, 9:32-36.
15. Giri S.N., Gurujeyalakshmi G., Wang Y. Suppression of bleomycin-induced increased production of nitric oxide and NF-kB activation by treatment with taurine and niacin. Adv. Exp. Med. Biol. 2000, 483:545-561.
16. Gurujeyalakshmi G., Wang Y., Giri S.N. Taurine and niacin block lung injury and fibrosis by down-regulating bleomycin-induced activation of transcription nuclear factor-kappaB in mice. J. Pharmacol. Exp. Therap. 2000, 293:82-90.
17. Hagar H.H. The protective effect of taurine against cyclosporine A-induced oxidative stress and hepatotoxicity in rats. Toxicol. Lett. 2004, 151:335-343.
18. Hansen S.H. The role of taurine in diabetes and the development of diabetic complications. Diabetes/Metab. Res. Rev. 2001, 17:330-346.
19. Huxtable R.J. Physiological actions of taurine. Physiol. Rev. 1992, 72:101-163.
20. Ito T., Schaffer S.W., Azuma J. The potential usefulness of taurine on diabetes mellitus and its complications. Amino Acids 2012, 42:1529-1539.
21. Itoh K., Wakabayashi N., Katoh Y., Ishii T., Igarashi K., Engel J.D., Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999, 13:76-86.
22. Itoh K., Tong K.I., Yamamoto M. Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles. Free Radical Biol. Med. 2004, 36:1208-1213.
23. Jacobsen J.G., Smith L.H. Biochemistry and physiology of taurine and taurine derivatives. Am. Physiol. Soc. 1968, 48:429-511.
24. Jaiswal A.K. Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radical Biol. Med. 2004, 36:1199-1207.
25. Kainulainen H., Schumann A., Vilja P., Joost H.G. In-vivo glucose uptake and glucose transporter proteins GLUT1 and GLUT3 in brain tissue from streptozotocin-diabetic rats. Acta Physiol. Scand. 1993, 149:221-225.
26. Kuhad A., Chopra K. Attenuation of diabetic nephropathy by tocotrienol: involvement of NFkB signaling pathway. Life Sci. 2009, 84:296-301.
27. Kumar A., Sharma S.S. NF-kappaB inhibitory action of resveratrol: a probable mechanism of neuroprotection in experimental diabetic neuropathy. Biochem. Biophys. Res. Commun. 2010, 394:360-365.
28. Kumar A., Negi G., Sharma S.S. JSH-23 targets nuclear factor kappa B (NF-kappaB) and reverses various deficits in experimental diabetic neuropathy: effect on neuroinflammation and antioxidant defence. Diabetes Obes. Metab. 2011, 13:750-758.
29. Kumar A., Negi G., Sharma S.S. Suppression of NF-κB and NF-κB regulated oxidative stress and neuroinflammation by BAY 11-7082 (IκB phosphorylation inhibitor) in experimental diabetic neuropathy. Biochimie 2012, 94:1158-1165.
30. Li W., Kong A.N. Molecular mechanisms of Nrf2-mediated antioxidant response. Mol. Carcinog. 2009, 48:91-104.
31. Little A.A., Edwards J.L., Feldman E.L. Diabetic neuropathies. Pract. Neurol. 2007, 7:82-92.
32. Massa P.T., Aleyasin H., Park D.S., Mao X., Barger S.W. NFkappaB in neurons? The uncertainty principle in neurobiology. J. Neurochem. 2006, 97:607-618.
33. Maturo J., Kulakowski E.C. Taurine binding to the purified insulin receptor. Biochem. Pharmacol. 1988, 37:3755-3760.
34. McCrimmon R.J., Ryan C.M., Frier B.M. Diabetes and cognitive dysfunction. Lancet 2012, 16:2291-2299.
35. Mosley R.L., Benner E.J., Kadiu I., Thomas M., Boska M.D., Hasan K., Laurie C., Gendelman H.E. Neuroinflammation, oxidative stress and the pathogenesis of Parkinson's disease. Clin. Neurosci. Res. 2006, 6:261-281.
36. Motohashi H., Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol. Med. 2004, 10:549-557.
37. Negi G., Kumar A., Joshi R.P., Sharma S.S. Oxidative stress and Nrf2 in the pathophysiology of diabetic neuropathy: old perspective with a new angle. Biochem. Biophys. Res. Commun. 2011, 408:1-5.
38. Negi G., Kumar A., Sharma S.S. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-kappaB and Nrf2 cascades. J. Pineal Res. 2011, 50:124-131.
39. Nizamutdinova I.T., Jin Y.C., Chung J.I., Shin S.C., Lee S.J., Seo H.G., Lee J.H., Chang K.C., Kim H.J. The anti-diabetic effect of anthocyanins in streptozotocin-induced diabetic rats through glucose transporter 4 regulation and prevention of insulin resistance and pancreatic apoptosis. Mol. Nutr. Food Res. 2009, 53:1419-1429.
40. Obrosova I.G., Stevens M.J. Effect of dietary taurine supplementation on GSH and NAD(P)-redox status, lipid peroxidation, and energy metabolism in diabetic precataractous lens. Invest. Ophthalmol. Vis. Sci. 1999, 40:680-688.
41. Obrosova I.G., Fathallah L., Stevens M.J. Taurine counteracts oxidative stress and nerve growth factor deficit in early experimental diabetic neuropathy. Exp. Neurol. 2001, 172:211-219.
42. Pan C., Giraldo G.S., Prentice H., Wu J.Y. Taurine protection of PC12 cells against endoplasmic reticulum stress induced by oxidative stress. J. Biomed. Sci. 2010, 1:S17.
43. Pan C., Prentice H., Price A.L., Wu J.Y. Beneficial effect of taurine on hypoxia- and glutamate-induced endoplasmic reticulum stress pathways in primary neuronal culture. Amino Acid 2011, 43:1141-1146.
44. Pandya K.G., Patel M.R., Lau-Cam C.A. Comparative study of the binding characteristics to and inhibitory potencies towards PARP and in vivo antidiabetogenic potencies of taurine, 3-aminobenzamide and nicotinamide. J. Biomed. Sci. 2010, 24:S16.
45. Plaschke K., Hoyer S. Action of the diabetogenic drug streptozotocin on glycolytic and glycogenolytic metabolism in adult rat brain cortex and hippocampus. Int. J. Dev. Neurosci. 1993, 11:477-483.
46. Porte D., Baskin D.G., Schwartz M.W. Insulin signaling in the central nervous system: a critical role in metabolic homeostasis and disease from C. elegans to humans. Diabetes 2005, 54:1264-1276.
47. Rashid K., Das J., Sil P.C. Taurine ameliorate alloxan induced oxidative stress and intrinsic apoptotic pathway in the hepatic tissue of diabetic rats. Food Chem. Toxicol. 2013, 51:317-329.
48. Ravi K., Ramachandran B., Subramanian S. Effect of Eugenia Jambolana seed kernel on antioxidant defense system in streptozotocin-induced diabetes in rats. Life Sci. 2004, 75:2717-2731.
49. Reagan L.P., Magarinos A.M., Lucas L.R., Van Bueren A., McCall A.L., McEwen B.S. Regulation of GLUT-3 glucose transporter in the hippocampus of diabetic rats subjected to stress. Am. J. Physiol. 1999, 276:879-886.
50. Schaffer S.W., Azuma J., Mozaffari M. Role of antioxidant activity of taurine in diabetes. Can. J. Physiol. Pharmacol. 2009, 87:91-99.
51. Shanmugam K.R., Mallikarjuna K., Nishanth K., Kuo C.H., Reddy K.S. Protective effect of dietary ginger on antioxidant enzymes and oxidative damage in experimental diabetic rat tissues. Food Chem. 2011, 124:1436-1442.
52. Sima A.A., Sugimoto K. Experimental diabetic neuropathy: an update. Diabetologia 1999, 42:773-788.
53. Song F., Qi X., Chen W., Jia W., Yao P., Nussler A.K., Sun X., Liu L. Effect of Momordica grosvenori on oxidative stress pathways in renal mitochondria of normal and alloxan-induced diabetic mice. Involvement of heme oxygenase-1. Eur. J. Nutr. 2007, 46:61-69.
54. Song M.Y., Kim E.K., Moon W.S., Park J.W., Kim H.J., So H.S., Park R., Kwon K.B., Park B.H. Sulforaphane protects against cytokine- and streptozotocin-induced beta-cell damage by suppressing the NF-kappaB pathway. Toxicol. Appl. Pharmacol. 2009, 235:57-67.
55. Sun M., Gui Y., Zhao Y., Xu C. Protective functions of taurine against experimental stroke through depressing mitochondria mediated cell death in rats. Amino Acids 2011, 40:1419-1429.
56. Tappaz M., Almarghini K., Legay F., Remy A. Taurine biosynthesis enzyme cysteine sulfinate decarboxylase CSD from brain: the long and tricky trail to identification. Neurochem. Res. 1992, 17:849-859.
57. Terada T., Hara K., Haranishi Y., Sata T. Antinociceptive effect of intrathecal administration of taurine in rat models of neuropathic pain. Can. J. Anaesth. 2011, 58:630-637.
58. Van Dam P.S. Oxidative stress and diabetic neuropathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab. Res. Rev. 2002, 18:176-184.
59. Vannucci S.J., Clark R.R., Koehler-Stec E., Li K., Smith C.B., Davies P., Maher F., Simpson I.A. Glucose transporter expression in brain: relationship to cerebral glucose utilization. Dev. Neurosci. 1998, 20:369-379.
60. Vincent A.M., Russell J.W., Low P., Feldman E.L. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocrinol. Rev. 2004, 25:612-628.
61. Vincent A.M., Edwards J.L., Sadidi M., Feldman E.L. The antioxidant response as a drug target in diabetic neuropathy. Curr. Drug Targets 2008, 9:94-100.
62. Virgintino D., Robertson D., Monaghan P., Errede M., Bertossi M., Ambrosi G., Roncali L. Glucose transporter glut1 in human brain microvessels revealed by ultrastructural immunocytochemistry. J. Submicrosc. Cytol. Pathol. 1997, 29:365-370.
63. Yamamoto H., Uchigata Y., Okamoto H. Streptozotocin and alloxan induce DNA strand breaks and poly(ADP-ribose) synthetase in pancreatic islets. Nature 1981, 294:284-286.
64. Yao H.T., Lin P., Chang Y.W., Chen C.T., Chiang M.T., Chang L., Kuo Y.C., Tsai H.T., Yeh T.K. Effect of taurine supplementation on cytochrome P450 2E1 and oxidative stress in the liver and kidneys of rats with streptozotocin-induced diabetes. Food Chem. Toxicol. 2009, 47:1703-1709.